Ginkgo Bioworks heads into the back half of 2026 with a fresh downgrade, rising short interest, and a peer group that largely left it behind this week.
The analyst shift is the week's clearest development. TD Cowen's Brendan Smith downgraded Ginkgo to Hold from Buy on August 7, cutting his price target from $12 to $9 — and the stock at $7.97 is already trading through that new target. The only other active coverage is BTIG's standing Sell with a $5 target. That leaves the consensus at a single Hold, no buyers, and a mean target of $7.00 — implying the Street collectively sees the stock as roughly fairly valued at best, with meaningful downside risk from the sell-side dissenter. The downgrade is a genuine change to the story: Ginkgo had been carrying a Buy from one of its two covering analysts, and that support is now gone.
Short positioning tells a consistent story. At 12.5% of free float, short interest is elevated and has been climbing — up roughly 13% over the past month and 2% on the week, reaching its highest level of that 30-day window mid-week. The borrow market, however, is not signalling a squeeze in either direction. Cost to borrow is running at just 0.59% — low in absolute terms, though up 23% on the week, a move worth watching. Availability remains very loose at 364%, meaning there are more than three shares available to borrow for every share already shorted. The lending market is open; new short positions face no friction.
Options positioning adds little drama. The put/call ratio of 0.22 is almost exactly in line with its 20-day average of 0.21, and the z-score is effectively flat. That's a notably low PCR — well below the 52-week high of 0.73 — suggesting options traders are not hedging aggressively despite the price weakness. The combination of rising short interest and calm options markets points to a fundamental bear case being expressed through the stock itself, rather than through derivatives.
The peer divergence sharpens the picture. While Ginkgo dropped 1.5% on the week, ABCL jumped 21%, RGEN added 16%, TEM gained 19%, and QSI climbed 14%. The week's broad rally in life-science tools names passed Ginkgo by. Only PACB fared worse, falling 15%. The ORTEX short score of 60 places Ginkgo in moderately bearish territory, and the underlying fundamentals remain weak — a Piotroski F-score of 2, deeply negative return on assets, and sales declining 38% year-on-year, per the prior note history. The price-to-book of 1.1x is not egregiously stretched, but with no earnings path in view, it offers limited comfort.
The next scheduled earnings print is November 6. Between now and then, the key variable to watch is whether short interest continues its monthly uptrend as the analyst base narrows further, or whether the cost-to-borrow tick higher signals the beginning of a tighter borrow market.
See the live data behind this article on ORTEX.
Open DNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
